Efficacy of Ofloxacin in eradication of Helicobacter pylori

Adding Ofloxacin to standard regimens versus standard triple-drug regimens consist of Clarithromycin, Amoxicillin, and Rabeprazole for Helicobacter Pylori Infection among patients with gastrointestinal problems based on Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015113025292N1

Enrollment

160

Registered

2016-02-09

Start date

2014-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: In intervention group, standard regimen including Amoxicillin (1000 mg, Farabi company, Iran), Clarithromycin (500 mg, Farabi company, Iran), and Rabeprazole (20 mg, Farabi company, I

Treatment - Drugs

In intervention group, standard regimen including Amoxicillin (1000 mg, Farabi company, Iran), Clarithromycin (500 mg, Farabi company, Iran), and Rabeprazole (20 mg, Farabi company, Iran), with addin

In control group, standard regimen including Amoxicillin (1000 mg, Farabi company, Iran), Clarithromycin (500 mg, Farabi company, Iran), and Rabeprazole (20 mg, Farabi company, Iran) were prescribed t

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: positive biopsies of H. pylori; positive rapid urease test of H. pylori, stomach ulcer; duodenal ulcer; dyspepsia with indications of Helicobacter pylori eradication. Exclusion criteria: previous treatment for H. pylori; renal failure; receiving antibiotics during the previous last month; cirrhosis; pregnancy; breast feeding; gastric cancer.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
UBT (Urease Breath Test). Timepoint: 20 days after completing treatment. Method of measurement: Patients swallow urea labeled with an uncommon isotope, either radioactive carbon-14 or non-radioactive carbon-13. After10 to 30 minutes, the detection of isotope-labeled carbon dioxide in exhaled breath indicates that the urea was split.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoud Sadeghi Hadad zavareh

Babol University of Medical Science

drm_sadeghihz@yahoo.com+98 11 3223 8284

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026